Ipsen signs $1.8bn RNA drug alliance with Skyhawk

Ipsen has expanded its R&D pipeline once again, agreeing a $1.8 billion alliance with Skyhawk Therapeutics focused on the development of RNA-targeting therapies for rare neurological diseases.